SecBot SecBot
8-K ·Filed Aug 13, 2026

INKT

MiNK Therapeutics, Inc.
MIXED
Impact 6/10
Horizonmonths Processed3mo ago SEC0001193125-26-347907
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The early Phase 2 data and named-patient access program are positive catalysts but the stock remains a binary bet on the C-1300-02 trial outcome. With only $8.8M cash and no revenue, monitor cash runway closely, the next catalyst is additional Phase 2 data expected early 2027. The improved expense discipline is a modest positive but does not change the fundamental risk profile.

DirectionMixed
Confidencemedium
Horizonmonths

agenT-797

● Neutral Named in this 8-K
Impact
Phase
Phase 2
Time to market
agenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.
Next catalyst
None dated

What to watchThe next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.

Price Chart

Loading chart...

Executive Summary

MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with cash burn slowing to $0.7M from $9.5M to $8.8M. The key catalyst is the randomized Phase 2 trial of agenT-797 in acute lung injury showing early positive Day 28 signals, plus the first paid named-patient access program in Brazil establishing a potential revenue stream.

Key Financial Metrics

EPS
−$0.62
Rating
in line

Key Facts

  • Net loss improved to $3.1M in Q2 2026 from $4.2M in Q2 2025, a 26% reduction
  • Cash and equivalents $8.8M as of June 30, 2026, down from $9.5M at March 31, 2026
  • First patients in randomized Phase 2 trial C-1300-02 for agenT-797 in acute lung injury were alive at Day 28 with improved oxygenation and ventilator liberation
  • First paid international named-patient access program established in Brazil for agenT-797
  • U.S. clinical site activation underway for the Phase 2 trial; additional data expected early 2027
  • EPS of -$0.62 vs -$1.06 in prior year quarter; no consensus estimate provided for Q2 2026

Financial Impact

Net loss improved by $1.1M YoY to $3.1M; cash burn of $0.7M in Q2 2026 vs $4.6M in Q1 2026; cash runway at current burn rate approximately 12 months

net losscashcash burn

Risk Factors

  • Cash runway limited to ~12 months at current burn rate, likely requiring additional financing
  • Phase 2 data is from a small number of patients in an ongoing blinded trial, early observations may not be predictive of final results
  • Named-patient access program revenue is uncertain and subject to per-patient regulatory authorization
  • No approved products or revenue from commercial sales

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-347907
Document: inkt-20260813.htm0001193125-26-347907
Document: 0001193125-26-347907-index-headers.html0001193125-26-347907
Document: 0001193125-26-347907-index.html0001193125-26-347907
Document: 0001193125-26-347907.txt0001193125-26-347907
8-K Data (Synthetic)0001193125-26-347907

Track record

21 reports on INKT

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 Viewing No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (10h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026